BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

about

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

P2860

Q53686361-E17EFAA0-E4FC-4BB5-B811-7BE7413787C0

P2860

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Item

http://www.wikidata.org/entity/Q38694128

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

BRAF, KRAS and PIK3CA Mutation ...... Breast Cancer Cell Line Model

@en

type

Item

label

BRAF, KRAS and PIK3CA Mutation ...... Breast Cancer Cell Line Model

@en

prefLabel

BRAF, KRAS and PIK3CA Mutation ...... Breast Cancer Cell Line Model

@en

P1476

BRAF, KRAS and PIK3CA Mutation ...... Breast Cancer Cell Line Model

@en

P2093

Jesil Mathew

http://www.w3.org/2001/XMLSchema#string

Jitendra N Senapati

http://www.w3.org/2001/XMLSchema#string

Leslie Llewellyn

http://www.w3.org/2001/XMLSchema#string

Satyajit Patra

http://www.w3.org/2001/XMLSchema#string

Vanesa Young

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Comprehensive molecular portraits of human breast tumours

Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications

Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: implications for catalytic proton transfer and inhibitor design

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Cancer statistics, 2016

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Trastuzumab emtansine: mechanisms of action and drug resistance

P304

2209-2213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2017.18.8.2209

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28843257

http://www.w3.org/2001/XMLSchema#string

P932

5697482

http://www.w3.org/2001/XMLSchema#string

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

about

P2860

P2860

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932